A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Suspension Injection of Investigational Capsid Inhibitors Compared to Placebo in Healthy Adults

Exclusion Criteria

• •History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, neurological or psychiatric disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study intervention or interfering with the interpretation of data.
• •Abnormal blood pressure.
• •Lymphoma, leukemia, or any malignancy within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years.
• •Breast cancer within the past 10 years.
• •Current or chronic history of liver disease or known hepatic or biliary abnormalities.
• •History of sensitivity to any of the study interventions, a history of drug allergy or other allergy that contraindicates their participation.
• •The participant has an underlying skin disease or disorder that would interfere with assessment of injection sites.
• •Participants considered to have insufficient musculature to allow safe capsid inhibitor intramuscular (gluteus medius) administration.
• •History of or on-going high-risk behaviours that may put the participant at increased risk for HIV.
• •Past or intended use of over-the-counter or prescription medication including herbal medications.
• •Current enrollment or recent past participation in another investigational study.
• •Exposure to more than 4 investigational products within 12 months prior to dosing.
• •Alanine transaminase (ALT) ≥1.5x upper limit of normal (ULN), Total bilirubin ≥1.5x ULN (isolated total bilirubin \>1.5xULN), and/or estimated creatinine clearance (eGFR) of \<60 millilitre per minute (mL/min)/1.73 square meter (m\^2).
• •History of or current infection with hepatitis B or hepatitis C.
• •Positive SARS-CoV-2 polymerase chain reaction test, having signs and symptoms, or having contact with known coronavirus disease 2019 (COVID-19) positive person/s in the 14 days prior to inpatient admission.
• •Use of tobacco or nicotine-containing products, regular alcohol consumption and/or regular use of known drugs of abuse.
• •Positive HIV antibody/antigen test.
• •Abnormal electrocardiogram (ECG) parameters.
• •Evidence of previous myocardial infarction, any conduction abnormality, any significant arrhythmia, non-sustained or sustained ventricular tachycardia, and/or sinus pauses (\>3 seconds).
• •The participant has a tattoo or other dermatological condition overlying the location of injection or a prior history of silicone implants or fillers (gluteal) which may interfere with interpretation of injection site reactions or administration of study product.